Manila Times Business
NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
Acquisitions bring immediate $135,000 in monthly recurring revenue prior to near-term scaling initiatives; Transaction structured as non-dilutive to $MAJI shareholders. ORLANDO, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced a major milestone in its corporate growth strategy with the execution of Definitive Purchase Agreements to
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Joist AI Rebrands to Kantiv, Bringing Pursuit Intelligence to AEC Marketing Teams
Just now
Spectrotel and Meter Join Forces to Deliver a New Standard in Managed Enterprise Networking
Just now
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Just now
Adverse Effects of COVID Vaccine on Musculoskeletal Conditions Need Research, according to the Journal of American Physicians and Surgeons
Just now